RSIP Vision Names Moshe Safran as the CEO of New RSIP Vision USA Office

One of the global leaders in artificial intelligence, computer vision and deep learning, RSIP Vision announces the appointment of Moshe Safran as the CEO of the new RSIP Vision USA offices in Silicon Valley. He will be leading business development in the United States from Silicon Valley Location.

Ron Soferman, Founder & CEO, RSIP Vision, says, “As a company that aspires to develop the medical equipment of the future, we attach particular importance to the close link between the AI development team and the clinical work with doctors. The new office will allow very close collaboration from the planning phase to the practical application by the surgeon in the operating room. Moshe's leadership and the added value brought by RSIP Vision's methodology for the medical device industry is a major benefit for its clients”.

Safran joined RSIP Vision as an algorithm developer and served as the team leader and research scientist for eight years.

He led the execution of computer vision projects, from developing a patented algorithm for 3D reconstruction of heart chambers using parametric modeling, to semiconductor precise measurements, deep learning and more.

This is a great opportunity to increase our presence in Silicon Valley and collaborate with healthcare companies that need additional AI and computer vision support. It's always exciting to take part in something that will disrupt the industry.

Excited on the promotion, Safran, says, “This is a great opportunity to increase our presence in Silicon Valley and collaborate with healthcare companies that need additional AI and computer vision support. It's always exciting to take part in something that will disrupt the industry. It starts with the initial inspiration to pinpoint a particular need. Then our solution builds through a development phase and, eventually, goes through clinical studies which include critical feedback from physicians. With the new office we are closer to the major names in the medical equipment industry, our clients, their R&D teams and clinical sites”.